evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews · Skin

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 2 · 50%Moderate 1 · 25%High 0 · 0%

Moderate‐potency vs mild‐potency topical corticosteroid

Clinician‐reported signs of eczema: IGA (number with cleared or marked improvement); short term (earliest time within 1‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency probably leads to higher clinician‐reported signs of eczema: IGA (number with cleared or… compared with mild‐potency topical corticosteroid (moderate certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema

Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).

1 finding from 1 review

Moderate‐potency vs mild‐potency topical corticosteroid

Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema

It is very uncertain whether moderate‐potency changes systemic adverse events: abnormal cortisol; end of treatment (6‐28… compared with mild‐potency topical corticosteroid (very low certainty).

1 finding from 1 review